Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (2024)

Market Closed - OTC Markets

Other stock markets

03:57:52 2024-05-24 pm EDT
5-day change 1st Jan Change
0.1705 USD +0.89% Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (1) +19.23% +21.79%
Feb. 15 Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024
Feb. 14 Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Financials (USD)

Sales 2022 32.26M Sales 2023 34.16M Capitalization 29.4M
Net income 2022 8M Net income 2023 3M EV / Sales 2022 0.92x
Net cash position 2022 5.75M Net cash position 2023 3.94M EV / Sales 2023 0.75x
P/E ratio 2022

4.73x

P/E ratio 2023

9.34x

Employees 53
Yield 2022 *

-

Yield 2023

-

Free-Float 77.76%

More Fundamentals * Assessed data

Chart Elite Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Elite Pharmaceuticals, Inc.

Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System Stimulant CI
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR to Marketing Partner Prasco, LLC CI
Transcript : Elite Pharmaceuticals, Inc., Q2 2024 Earnings Call, Nov 15, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic Product CI
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer CI
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study CI
Transcript : Elite Pharmaceuticals, Inc., Q1 2024 Earnings Call, Aug 15, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Transcript : Elite Pharmaceuticals, Inc., 2023 Earnings Call, Jun 30, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial Officer CI
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product CI

More news

Latest transcript on Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (2)

Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024

More transcripts

Press releases Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 Ended December 31, 2023 and Provides Conference Call Information AQ
Elite Pharmaceuticals, Inc. To Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024 AQ
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant AQ
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 Ended September 30, 2023 and Provides Conference Call Information AQ
"Exploring Penny Stocks: Four Watchlist Options" FTRS, ELTP, ENZC, ZOM AQ

More press releases

Quotes and Performance

1 day+0.89%
1 week+19.23%
Current month+31.46%
1 month+28.68%
3 months+5.18%
6 months+8.60%
Current year+21.79%

More quotes

Highs and lows

1 week

0.15

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (3)

0.18

1 month

0.12

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (4)

0.18

Current year

0.12

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (5)

0.21

1 year

0.03

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (6)

0.21

3 years

0.02

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (7)

0.21

5 years

0.02

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (8)

0.21

10 years

0.02

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (9)

0.47

More quotes

Managers and Directors - Elite Pharmaceuticals, Inc.

Managers TitleAgeSince

Nasrat Hakim CEO

Chief Executive Officer 63 13-07-31

Carter Ward DFI

Director of Finance/CFO 59 09-06-30

Christopher Dick PSD

President 69 02-10-31
Members of the board TitleAgeSince

Jeffrey Whitnell BRD

Director/Board Member 68 09-10-22

Barry Dash BRD

Director/Board Member 93 05-03-31

Davis Caskey BRD

Director/Board Member 76 16-04-27

More insiders

Quotes

Date Price Change Volume
24-05-24 0.1705 +0.89% 818,984
24-05-23 0.169 +9.81% 1,314,734
24-05-22 0.1539 +2.26% 638,141
24-05-21 0.1505 +1.83% 374,122
24-05-20 0.1478 +3.36% 889,973

Delayed Quote OTC Markets, May 24, 2024 at 03:57 pm EDT

More quotes

Company Profile

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Phendimetrazine Tartrate 35mg tablets, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.

Sector

Pharmaceuticals

Calendar

2024-06-11 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.

ELITE PHARMACEUTICALS, INC.

+21.79% 182M

SUN PHARMACEUTICAL INDUSTRIES LTD.

+18.04% 42.95B

OTSUKA HOLDINGS CO., LTD.

+15.75% 21.38B

SANDOZ GROUP AG

+18.33% 15.05B

CIPLA LIMITED

+19.27% 14.45B

ZYDUS LIFESCIENCES LIMITED

+56.12% 13.04B

THE MEDICINES COMPANY

-0.05% 6.79B

ONO PHARMACEUTICAL CO., LTD.

-12.92% 6.72B

STADA ARZNEIMITTEL

-8.87% 5.73B

ASPEN PHARMACARE HOLDINGS LIMITED

+11.21% 5.47B

Generic Pharmaceuticals

  1. Stock Market
  2. Equities
  3. ELTP Stock

Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (20)

"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '120786915');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });
Elite Pharmaceuticals, Inc. Stock (ELTP) - Quote OTC Markets- MarketScreener (2024)
Top Articles
Latest Posts
Article information

Author: Nathanael Baumbach

Last Updated:

Views: 6485

Rating: 4.4 / 5 (75 voted)

Reviews: 82% of readers found this page helpful

Author information

Name: Nathanael Baumbach

Birthday: 1998-12-02

Address: Apt. 829 751 Glover View, West Orlando, IN 22436

Phone: +901025288581

Job: Internal IT Coordinator

Hobby: Gunsmithing, Motor sports, Flying, Skiing, Hooping, Lego building, Ice skating

Introduction: My name is Nathanael Baumbach, I am a fantastic, nice, victorious, brave, healthy, cute, glorious person who loves writing and wants to share my knowledge and understanding with you.